This sale of common stock was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 5, 2013.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $35.14 to $35.59.
Includes 4,500 restricted stock units awarde
d January 27, 2011, of which 1/3 of the shares vest on February 15, 2014, and the 1/3 of the shares that vested on each of February 15, 2012 and 2013, net of withholding.
Includes 5,700 restricted stock units awarded February 5, 2012 which vest as to 1/3 of the shares on February 15, 2014 and 2015, and the 1/3 of the shares that vested on February 15, 2013, net of withholding.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here. Genomic Health next reports earnings on August 05, 2013.
To receive a free e-mail notification whenever Genomic Health makes a similar move, sign up!